Back to companies

Shanghai Henlius Biotech Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $125 per month (billed Annually)
Download a free sample

Shanghai Henlius Biotech Inc (Henlius) is a biopharmaceutical company, which is involved in the research, development, production, and marketing of monoclonal antibody products. It develops medicines primarily for oncology, autoimmune and ophthalmic diseases. The company’s key products include Rituximab injection for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma; Trastuzumab for breast cancer, metastatic gastric cancer and metastatic breast cancer; and Adalimumab injection for ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis and uveitis. It is also focusing on developing other products such as HLX14, HLX10, Serplulimab+Chemo, HLX208, HLX13 and HLX71 among other, which are under research and clinical trials. Henlius operates R&D centers in Shanghai, China, and California, the US. Shanghai Henlius Biotech is headquartered in Xuhui District, Shanghai, China.

Headquarters China

Address Building C, No. 1289 Yishan Road, Xuhui District, Shanghai, 200233


Telephone 86 21 33395800

No of Employees 1,972

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 2696 (HKG)

Revenue (2020) $85.2M 546.2% (2020 vs 2019)

EPS XXX

Net Income (2020) XXX -13.5% (2020 vs 2019)

Market Cap* $1.6B

Net Profit Margin (2020) XXX 82.4% (2020 vs 2019)

* As of and is in US$

Products and Services

Products
Rituximab Injection
Trastuzumab
Adalimumab Injection
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Others In November, the company announced successful completion of Phase 1 clinical trial of Pertuzumab Biosimilar HLX11.
2021 Regulatory Approval In November, the company secured an approval from Bellberry Human Research Ethics Committee for its novel anti PD-L1/TIGIT bispecific antibody.
2021 Contracts/Agreements In August, the company and Shanghai Promega Biological Products announced to develop and commercialize a microsatellite instability companion diagnostic IVD kit.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Shanghai Henlius Biotech Inc Tianjin Tianyao Pharmaceutical Co Ltd Sihuan Pharmaceutical Holdings Group Ltd China Pharma Holdings Inc China Meheco Topfond Pharma Co Ltd
Headquarters China China China China China
City Shanghai Tianjin Beijing Haikou Zhumadian
State/Province Shanghai Tianjin Beijing Hainan Henan
No. of Employees 1,972 2,943 4,223 237 4,434
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Sales Growth
Image for loader
Net Income Growth
Image for loader
Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Chen Qiyu Chairman Executive Board 2018 48
Zhang Wenjie President; Chief Executive Officer Senior Management 2020 54
Xinlei Li Vice President; Chief Financial Officer Senior Management 2020 39
Zhang Zidong Chief Financial Officer Senior Management - -
Xu Shengchang Chief Technology Officer; Senior Vice President Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer